RetinalGenix Technologies Inc
retinalgenix.comWhat Do They Do?
Develops genetic tests, retinal imaging devices and patient-controlled health data tools for patients and clinicians, alongside drug candidates for eye and systemic diseases.
10-K for FY2025, filed Apr 15, 2026RetinalGenix Technologies Inc. (“RetinalGenix” or the “Company”) is an ophthalmic research and development company focused on developing…View ↗
Our products and services are built on four pillars: (i) genetic testing; (ii) retinal imaging; (iii) patient information base and (iv)…View ↗
Our wholly owned subsidiary, DNA/GPS Inc., through pharmacogenetic mapping and testing is linking high resolution retinal imaging to…View ↗
We are developing a secure and interoperable database system for genetic information and images controlled by patients for use with their…View ↗
Pharmaceutical Therapies: Developing pharmaceutical products for treating eye and systemic diseases with partnered support, with RTG-2023…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Apr 15, 2026
Who Are Their Customers?
Patients are expected to buy genetic test kits, with a third-party company handling manufacturing, distribution, clinical processing and reporting. Patients and physicians are also intended users of the imaging and information tools.
10-K for FY2025, filed Apr 15, 2026Patients will be able to purchase and use these swab-based tests that will identify their genetic profiles with our third-party partner.…View ↗
In 2026, we intend to begin selling these tests to patients. A third-party genetic testing company will provide manufacturing…View ↗
This RetinalCamTM is an economical portable camera for ophthalmic home screening and monitoring. This device will provide remote general…View ↗
The Company is developing a secure and interoperable database system for genetic information and images controlled by patients for use with…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$307.4KView ↗
- ▼ −53% (Loss)
- vs −$649.4K in Q2 FY2025
-
Jul 15, 2026
The company changed its independent auditor
Liebman Hymowitz resigned, and Vilki & Co. was engaged as the independent auditor for 2026.
Sources
8-K, filed Jul 15, 2026
On July 13, 2026, RetinalGenix Technologies Inc. (the “Company”) received written notice from Liebman Hymowitz, LLP (“LH”) that LH will be…View ↗
Added genetic testing and therapies
The older report centered on retinal imaging devices and described recently acquired genetic mapping technology. The latest report adds planned genetic test kits, a patient-controlled health information database, and pharmaceutical candidates for eye and systemic diseases.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Apr 15, 2026Our products and services are built on four pillars: (i) genetic testing; (ii) retinal imaging; (iii) patient information base and (iv)…View ↗
We are developing a secure and interoperable database system for genetic information and images controlled by patients for use with their…View ↗
Pharmaceutical Therapies: Developing pharmaceutical products for treating eye and systemic diseases with partnered support, with RTG-2023…View ↗
Through RetinalGenix’s DNA/GPS Inc and supported by partnered organizations, we are developing genetic testing kits. The DNA/GPS Inc.…View ↗
Who Do They Compete With?
Competes with Optomed, Optos, and Zeiss
10-K for FY2022, filed Mar 31, 2023The ophthalmic medical technology industries utilize rapidly advancing technologies and are characterized by intense competition. There is…View ↗
Loading...
